Olink Bioscience this week launched its Proseek Multiplex multiplexed protein biomarker immunoassays. According to the Uppsala, Sweden-based firm, Proseek Multiplex enables users to quantify 92 proteins in a 1 microliter sample "without compromising data quality or performance."
The new offering is based on Olink's proximity extension assay platform. PEA uses pairs of antibodies equipped with DNA reporter molecules, which, upon target binding, give rise to new DNA amplicons that barcode their respective antigens for downstream identification. The amplicons are subsequently quantified by real-time PCR.
CEO Simon Fredriksson said in a statement that Olink intends to introduce a portfolio of protein biomarker assays. First in this range is its Proseek Multiplex Oncology I 96x96 kit, which is capable of analyzing 96 samples against a panel of analytes such as growth factors, inflammatory markers, soluble receptors, and cancer antigens. Fredriksson said that Olink plans to launch additional Proseek 92-plex panels for cardiovascular disease, inflammation, and diabetes this year.